# Topical Composition Therapy for the Treatment of Cutaneous Mastocytosis

> **NCT04846348** · PHASE2 · TERMINATED · sponsor: **Joseph Butterfield** · enrollment: 1 (actual)

## Conditions studied

- Cutaneous Mastocytoses

## Interventions

- **COMBINATION_PRODUCT:** Topical preparation of sodium cromolyn 5%, diphenhydramine 1% and trolamine salicylate 10% in emollient cream base.

## Key facts

- **NCT ID:** NCT04846348
- **Lead sponsor:** Joseph Butterfield
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-07-26
- **Primary completion:** 2021-09-10
- **Final completion:** 2021-09-10
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** It was difficult to enroll patients during the pandemic. A new oral drug, Avapritinib, has since been approved for systemic mastocytosis. This medication controls skin manifestations of mastocytosis and is more convenient for patients to use.
- **Last updated:** 2024-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04846348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04846348, "Topical Composition Therapy for the Treatment of Cutaneous Mastocytosis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04846348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*